Insmed, Inc.
INSM
$124.89
-1.11%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, with its commercial portfolio and clinical pipeline organized around respiratory, immunology/inflammation, and neuro/other rare therapeutic areas. The company's marketed products, Arikayce and Brinsupri, target respiratory conditions, while its pipeline includes promising candidates like brensocatib for bronchiectasis and other inflammatory diseases, positioning Insmed as a specialized player in the rare disease space. Currently, investor attention centers on the commercial ramp of Arikayce and the potential of brensocatib, which has shown positive Phase 3 data and could significantly expand the company's addressable market. However, the stock has experienced volatility due to clinical trial readouts, competitive pressures in the PAH space, and the company's ongoing path to profitability, making it a high-risk, high-reward opportunity in the biotech sector.…
INSM
Insmed, Inc.
$124.89
Related headlines
Investment Opinion: Should I buy INSM Today?
Based on the data, INSM is rated a Buy. The consensus recommendation is Strong Buy with an average target price of $200.18, implying 58.5% upside. The thesis is driven by the potential of brensocatib to become a blockbuster drug, which could transform the company's revenue and profitability. Supporting evidence includes a high gross margin of 83.8%, sequential revenue growth from $263.8M in Q4 2025 to $305.96M in Q1 2026, and a strong balance sheet with a current ratio of 3.83. The forward PE of 157.4x is not meaningful given current losses, but the PS ratio of 61.3x, while high, is within the company's historical range of 35x-214x, suggesting it is not at an extreme. The main risks are the high cash burn and the binary outcome of brensocatib's commercial success. This Buy would be downgraded to Hold if brensocatib fails to gain regulatory approval or if revenue growth decelerates below 10% YoY. Conversely, it could be upgraded if the company achieves profitability sooner than expected. Overall, INSM is fairly valued relative to its growth potential, but investors must be prepared for volatility.
Sign up to view all
INSM 12-Month Price Forecast
The AI assessment is bullish on INSM over the next 12 months, driven by the strong analyst consensus, improving revenue trends, and the high probability of brensocatib's approval. The main risk is the extreme valuation, which leaves little room for error. If brensocatib succeeds, the stock could reach the high target of $243; if it fails, the downside to $90 is significant. The stance would be upgraded to high confidence if brensocatib receives approval and initial sales exceed expectations, or downgraded to neutral if clinical data disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $200.18 and implied upside of +60.3% versus the current price.
Average Target
$200.18
0 analysts
Implied Upside
+60.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$169 - $243
Analyst target range
Insmed is covered by 22 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.22 (where 1 is Strong Buy and 5 is Sell). The average price target is $200.18, implying a substantial upside of 58.5% from the current price of $126.29. The distribution of ratings is heavily skewed toward buy, with no sell ratings, indicating strong bullish sentiment among analysts. The target price range spans from $169.00 to $243.00, with the low target still representing a 33.8% upside, suggesting that even the most bearish analyst sees significant value. The high target of $243.00 implies a potential gain of 92.4%, likely reflecting optimism about brensocatib's commercial success and revenue growth. Recent institutional ratings from firms like Wells Fargo, Guggenheim, and JP Morgan have all been positive, with actions such as 'Overweight' and 'Buy', and no downgrades have been observed in the recent data, reinforcing the bullish outlook. The wide spread between the low and high targets (74 points) indicates high uncertainty about the company's future, but the overall consensus is overwhelmingly positive, driven by the potential of the pipeline and commercial execution.
Drowning in data?
Find the real signal!
Bulls vs Bears: INSM Investment Factors
Insmed presents a classic high-risk, high-reward biotech opportunity. The bull case is anchored by a Strong Buy analyst consensus, a robust pipeline with brensocatib's blockbuster potential, and improving revenue trends. However, the bear case is equally compelling, with extreme valuation multiples, deep cash burn, and persistent losses. Currently, the bull side has stronger evidence given the unanimous analyst support and the potential for brensocatib to drive exponential growth. The central tension is whether the market's high expectations for brensocatib's commercial success will materialize; if clinical or commercial execution falters, the stock could face severe downside, but if successful, the upside is substantial.
Bullish
- Strong Buy consensus with 58.5% upside: 22 analysts rate INSM a Strong Buy (mean score 1.22), with an average price target of $200.18, implying 58.5% upside from the current $126.29. Even the lowest target of $169.00 offers 33.8% upside, and no sell ratings exist, reflecting overwhelming bullish sentiment.
- High gross margin of 83.8%: Q1 2026 gross margin reached 83.8%, up from 77.1% in Q1 2025, indicating strong pricing power and cost efficiency in commercial products. This high margin provides a solid foundation for future profitability as revenue scales.
- Revenue growth accelerating sequentially: Q1 2026 revenue of $305.96 million grew 2.3% YoY, but more importantly, it jumped from $263.8 million in Q4 2025 and $142.3 million in Q3 2025, showing a clear upward trajectory. This sequential acceleration suggests successful commercial execution for Arikayce and Brinsupri.
- Pipeline potential with brensocatib: Brensocatib has shown positive Phase 3 data for bronchiectasis, a condition with no approved therapies, representing a significant market opportunity. Analysts' high target of $243.00 (92.4% upside) likely reflects expectations of this drug's blockbuster potential, which could transform the company's revenue base.
Bearish
- Deeply negative free cash flow of -$951.6M: TTM free cash flow is -$951.6 million, reflecting heavy investment in R&D and commercialization. This cash burn requires continuous external financing, which could lead to dilution or increased debt, pressuring shareholder value.
- Extreme valuation at 61.3x PS: INSM trades at 61.3x trailing sales, far above the biotech industry average of ~10x. Even EV/Sales of 23.9x is elevated, leaving little room for error. If growth disappoints, the stock could face severe multiple compression.
- Persistent operating losses: Q1 2026 operating loss was -$200.3 million, with an operating margin of -65.5%. While losses are narrowing from -$366.0 million in Q3 2025, the company remains far from profitability, and R&D expenses of $209.5 million continue to outpace revenue growth.
- High debt-to-equity ratio of 1.04: Insmed's debt-to-equity ratio of 1.04 indicates moderate leverage, which could strain cash flows if interest rates remain high. Interest expense of $20.1 million in Q1 2026 adds to the financial burden, reducing funds available for operations.
INSM Technical Analysis
Insmed's stock is currently in a recovery phase after a significant drawdown, trading at $126.29 as of September 4, 2026, which is 59.4% of its 52-week range (low of $90.39 and high of $212.75). The 1-year price change is -11.4%, indicating a net decline over the past year, but the stock has rebounded strongly from its June low of $91.88, suggesting a potential trend reversal. The stock's beta of 0.817 indicates it is less volatile than the broader market, which may appeal to risk-averse investors, but the 52-week range shows substantial volatility, with the stock having fallen over 56% from its high at one point.
Beta
0.82
0.82x market volatility
Max Drawdown
-56.5%
Largest decline past year
52-Week Range
$90-$213
Price range past year
Annual Return
-14.9%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -4.7% | -0.9% |
| 3m | +35.9% | +5.6% |
| 6m | -10.5% | +15.0% |
| 1y | -14.9% | +18.1% |
| ytd | -29.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Insmed's revenue has grown significantly, with Q1 2026 revenue of $305.96 million, up 2.3% year-over-year, but this growth rate is a slowdown from the triple-digit growth seen in earlier quarters when revenue was much lower (e.g., Q2 2025 revenue was $107.4 million). The company's gross margin is high at 83.8% in Q1 2026, reflecting the profitability of its commercial products, but operating expenses, particularly R&D ($209.5 million in Q1 2026), remain substantial, leading to an operating loss of $200.3 million. Net income for Q1 2026 was -$163.6 million, with an EPS of -$0.76, and while losses are narrowing from the -$1.75 EPS in Q3 2025, the company remains far from profitability. Insmed's balance sheet shows a debt-to-equity ratio of 1.04, indicating moderate leverage, and a current ratio of 3.83, suggesting strong short-term liquidity. However, the company's free cash flow is deeply negative at -$951.6 million on a TTM basis, and it has relied on equity and debt financing to fund operations, as seen in the $860.5 million raised from stock issuance in Q2 2025.
Quarterly Revenue
$305964000.0B
2026-03
Revenue YoY Growth
+229.6%
YoY Comparison
Gross Margin
83.8%
Latest Quarter
Free Cash Flow
$-951635000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given Insmed's negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales (PS) ratio, which stands at 61.3x trailing revenue, while the EV/Sales ratio is 23.9x. The forward PE ratio of 157.4x is not meaningful given the company's current losses, but it reflects the market's expectation of future profitability, likely driven by brensocatib's potential. Compared to the biotechnology industry average PS ratio of around 10x, Insmed trades at a significant premium, which is justified by its high revenue growth and the blockbuster potential of its pipeline, but it also leaves little room for error. Historically, Insmed's PS ratio has ranged from 35x to 214x over the past two years, and the current 61.3x is near the lower end of that range, suggesting that the stock may be undervalued relative to its own history, but this could also reflect reduced growth expectations or increased risk perception.
PE
-27.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Insmed's free cash flow is deeply negative at -$951.6 million TTM, indicating heavy reliance on external financing. The company has a debt-to-equity ratio of 1.04, and interest expenses of $20.1 million per quarter add to the cash burn. While the current ratio of 3.83 provides near-term liquidity, the persistent operating losses (Q1 2026 operating loss of -$200.3 million) and high R&D spending ($209.5 million in Q1) mean the company will likely need to raise additional capital, potentially diluting existing shareholders. Revenue concentration in respiratory products (Arikayce and Brinsupri) also exposes the company to competitive pressures and regulatory changes in that niche.
FAQ
The key risks of holding INSM include: 1) Clinical and regulatory risk - brensocatib could fail in trials or face approval delays, which would severely impact the stock. 2) Financial risk - the company has a deep negative free cash flow of -$951.6M TTM and may need to raise capital, causing dilution. 3) Valuation risk - the stock trades at 61.3x PS, leaving little room for error; any growth slowdown could lead to a sharp de-rating. 4) Competitive risk - increased competition in the PAH space, as noted in recent news about LQDA's Yutrepia, could pressure Arikayce sales. The most severe risk is a clinical failure, which could send the stock down 28% to the 52-week low.
The 12-month forecast for INSM is bullish, with a base case probability of 45% targeting the analyst average of $200.18 (58.5% upside). The bull case (35% probability) targets $243.00 (92.4% upside) if brensocatib launches successfully, while the bear case (20% probability) could see the stock fall to $90.39 (-28.4%) if clinical or regulatory setbacks occur. The most likely scenario is the base case, which assumes brensocatib progresses without major issues and revenue growth continues. Investors should monitor brensocatib's regulatory timeline and commercial performance closely.
INSM trades at 61.3x trailing sales, which is significantly higher than the biotech industry average of ~10x, indicating a premium valuation. However, this premium is justified by the company's high revenue growth and the blockbuster potential of brensocatib. Historically, INSM's PS ratio has ranged from 35x to 214x over the past two years, and the current 61.3x is near the lower end, suggesting the stock may be undervalued relative to its own history. The market is pricing in high expectations for future growth, and any disappointment could lead to multiple compression.
INSM is a good buy for investors with a high risk tolerance and a long-term horizon, given the strong analyst consensus (Strong Buy, average target $200.18, 58.5% upside) and the potential of brensocatib. However, the stock is highly volatile and carries significant risk due to its extreme valuation (61.3x PS) and negative cash flow. The biggest downside risk is a clinical failure or regulatory setback for brensocatib, which could send the stock to the 52-week low of $90.39. For those who believe in the pipeline, the risk/reward is attractive, but it is not suitable for conservative investors.
INSM is more suitable for long-term investment, given its early-stage pipeline and potential for multi-year growth. The stock's beta of 0.817 is lower than the market, but its 52-week range shows high volatility, making it risky for short-term trading. The company is not profitable and does not pay a dividend, so returns depend on capital appreciation driven by clinical and commercial milestones. A minimum holding period of 3-5 years is recommended to allow brensocatib to reach the market and achieve peak sales. Short-term traders may find opportunities around clinical data readouts, but the risk is substantial.
